Aspirin Ameliorates Lung Cancer by Targeting the MiR-98/WNT1 Axis

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2019 Feb 14

PMID 30756509

Citations 18

Authors

HuiZhu Gan

Lin Lin

Nanjun Hu

Yang Yang

Yu Gao

Yu Pei

Kang Chen

Butong Sun

Affiliations

Soon will be listed here.

Abstract

Background: Aspirin, an anti-inflammatory drug, has been widely investigated in the treatment of many cancer types, including colorectal, ovarian, breast, and prostate cancers. MicroRNAs (miRNAs) are the most well studied noncoding RNAs in cancers. In the current study, we were interested in defining the function of aspirin in lung cancer treatment and the related noncoding RNAs involved in this process.

Methods: The function of aspirin in lung cancer growth was evaluated by cell viability and colony formation assays. Screening of miRNAs affected by aspirin was performed through quantitative real-time PCR. Prediction of miR-98 targeting WNT1 was performed using online bioinformatics software and was further confirmed by luciferase reporter gene analysis. The levels of miR-98 and WNT1 were tested through immunoblotting and quantitative real-time PCR analysis in lung cancer cells under aspirin treatment.

Results: Cell viability was sharply suppressed in lung cancer cells with an increasing dose of aspirin. Aspirin markedly weakened the malignant colony formation ability of lung cancer cells. One out of six tumor suppressor miRNAs could be obviously regulated by aspirin in lung cancer cells. The inhibition of miR-98 on the luciferase activities of wild-type 3' untranslated region vectors of WNT1 was clearly revealed in lung cancer cells. Meanwhile, the inhibitor of miR-98 increased the luciferase activities of wild-type 3' untranslated region vectors of WNT1. After treatment with aspirin the expression of miR-98 was induced and then its target gene, WNT1, was depressed in the cells.

Conclusion: Aspirin targets the miR-98/WNT1 axis to ameliorate lung cancer development.

Citing Articles

Aspirin in Cancer Therapy: Pharmacology and Nanotechnology Advances.

Laila U, Zhao Z, Liu H, Xu Z Int J Nanomedicine. 2025; 20:2327-2365.

PMID: 40017626 PMC: 11866938. DOI: 10.2147/IJN.S505636.

MicroRNA-98: the multifaceted regulator in human cancer progression and therapy.

Hazari V, Samali S, Izadpanahi P, Mollaei H, Sadri F, Rezaei Z Cancer Cell Int. 2024; 24(1):209.

PMID: 38872210 PMC: 11177407. DOI: 10.1186/s12935-024-03386-2.

Beyond Hormones: Investigating the Impact of Progesterone Receptor Membrane Component 1 in Lung Adenocarcinoma.

Solairaja S, Venkatabalasubramanian S J Membr Biol. 2024; 257(3-4):231-243.

PMID: 38546883 DOI: 10.1007/s00232-024-00311-6.

Mechanism of miR-98-5p in gastric cancer cell proliferation, migration, and invasion through the USP44/CTCFL axis.

Zhang K, Zhao J, Bi Z, Feng Y, Zhang H, Zhang J Toxicol Res (Camb). 2024; 13(2):tfae040.

PMID: 38500512 PMC: 10944557. DOI: 10.1093/toxres/tfae040.

Aspirin and Cancer Survival: An Analysis of Molecular Mechanisms.

Pandey M, Rajput M, Singh P, Shukla M, Zhu B, Koshiol J Cancers (Basel). 2024; 16(1).

PMID: 38201650 PMC: 10778469. DOI: 10.3390/cancers16010223.

References

Trabert B, Ness R, Lo-Ciganic W, Murphy M, Goode E, Poole E . Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst. 2014; 106(2):djt431. PMC: 3924755. DOI: 10.1093/jnci/djt431. View

Benamouzig R, Uzzan B, Martin A, Deyra J, Little J, Girard B . Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention. Gut. 2010; 59(5):622-9. DOI: 10.1136/gut.2008.175406. View

Huo X, Zhang X, Yu C, Cheng E, Zhang Q, Dunbar K . Aspirin prevents NF-κB activation and CDX2 expression stimulated by acid and bile salts in oesophageal squamous cells of patients with Barrett's oesophagus. Gut. 2017; 67(4):606-615. PMC: 5656558. DOI: 10.1136/gutjnl-2016-313584. View

Ding L, Yao W, Lu J, Gong J, Zhang X . Upregulation of circ_001569 predicts poor prognosis and promotes cell proliferation in non-small cell lung cancer by regulating the Wnt/β-catenin pathway. Oncol Lett. 2018; 16(1):453-458. PMC: 6006269. DOI: 10.3892/ol.2018.8673. View

Beermann J, Piccoli M, Viereck J, Thum T . Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches. Physiol Rev. 2016; 96(4):1297-325. DOI: 10.1152/physrev.00041.2015. View

Rothwell P, Wilson M, Price J, Belch J, Meade T, Mehta Z . Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012; 379(9826):1591-601. DOI: 10.1016/S0140-6736(12)60209-8. View

Berindan-Neagoe I, Del C Monroig P, Pasculli B, Calin G . MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin. 2014; 64(5):311-36. PMC: 4461198. DOI: 10.3322/caac.21244. View

Shen J, Zhou W, Bi N, Song Y, Zhang F, Zhan Q . MicroRNA-886-3P functions as a tumor suppressor in small cell lung cancer. Cancer Biol Ther. 2018; 19(12):1185-1192. PMC: 6301808. DOI: 10.1080/15384047.2018.1491505. View

He X, Chen S, Yang Z, Zhang J, Wang W, Liu M . miR-4317 suppresses non-small cell lung cancer (NSCLC) by targeting fibroblast growth factor 9 (FGF9) and cyclin D2 (CCND2). J Exp Clin Cancer Res. 2018; 37(1):230. PMC: 6145328. DOI: 10.1186/s13046-018-0882-4. View

10.

Li P, Wu H, Zhang H, Shi Y, Xu J, Ye Y . Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. Gut. 2014; 64(9):1419-25. DOI: 10.1136/gutjnl-2014-308260. View

11.

Liu Z, Yan Y, Cao S, Chen Y . Long non-coding RNA SNHG14 contributes to gastric cancer development through targeting miR-145/SOX9 axis. J Cell Biochem. 2018; 119(8):6905-6913. DOI: 10.1002/jcb.26889. View

12.

Yin Q, Han Y, Zhu D, Li Z, Shan S, Jin W . miR-145 and miR-497 suppress TGF-β-induced epithelial-mesenchymal transition of non-small cell lung cancer by targeting MTDH. Cancer Cell Int. 2018; 18:105. PMC: 6062944. DOI: 10.1186/s12935-018-0601-4. View

13.

Sitia G, Iannacone M, Guidotti L . Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. J Hepatol. 2013; 59(5):1135-8. DOI: 10.1016/j.jhep.2013.05.040. View

14.

Downer M, Allard C, Preston M, Gaziano J, Stampfer M, Mucci L . Regular Aspirin Use and the Risk of Lethal Prostate Cancer in the Physicians' Health Study. Eur Urol. 2017; 72(5):821-827. DOI: 10.1016/j.eururo.2017.01.044. View

15.

Liu C, Hu W, Li L, Wang Y, Zhou Q, Zhang F . Roles of miR-200 family members in lung cancer: more than tumor suppressors. Future Oncol. 2018; 14(27):2875-2886. DOI: 10.2217/fon-2018-0155. View

16.

Galipeau P, Li X, Blount P, Maley C, Sanchez C, Odze R . NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 2007; 4(2):e67. PMC: 1808095. DOI: 10.1371/journal.pmed.0040067. View

17.

Mattick J . The functional genomics of noncoding RNA. Science. 2005; 309(5740):1527-8. DOI: 10.1126/science.1117806. View

18.

Jiang F, Yu Q, Chu Y, Zhu X, Lu W, Liu Q . MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1. Int J Oncol. 2018; 54(1):128-138. PMC: 6255066. DOI: 10.3892/ijo.2018.4610. View

19.

Fang C, Chen P, Ho D, Tsai L, Hsieh P, Lu M . miR-145 mediates the anti-cancer stemness effect of photodynamic therapy with 5-aminolevulinic acid (ALA) in oral cancer cells. J Formos Med Assoc. 2018; 117(8):738-742. DOI: 10.1016/j.jfma.2018.05.018. View

20.

Yuan Y, Haiying G, Zhuo L, Ying L, Xin H . Long non-coding RNA LINC00339 facilitates the tumorigenesis of non-small cell lung cancer by sponging miR-145 through targeting FOXM1. Biomed Pharmacother. 2018; 105:707-713. DOI: 10.1016/j.biopha.2018.06.022. View